Core Viewpoint - Long-term investing in struggling stocks can yield significant benefits as companies recover and grow, allowing investors to buy at reasonable prices [1][2]. Group 1: Pfizer - Pfizer's revenue peaked at $100 billion due to coronavirus product sales but has since declined as demand waned and patents expired [4]. - The current trading price of Pfizer is $27.00, with a market cap of $153 billion and a forward earnings multiple of 9x, indicating it is a bargain for long-term investors [5][6][7]. - Pfizer is pursuing growth through acquisitions, including Seagen for oncology drugs and Metsera for a late-stage obesity drug candidate [6]. Group 2: UnitedHealth Group - UnitedHealth Group has faced challenges due to underestimated healthcare costs and service usage, impacting growth [8]. - The current trading price of UnitedHealth is $275.59, with a market cap of $250 billion and a forward earnings multiple of 15x, presenting a strong buying opportunity [9][11]. - The company is implementing strategies such as cutting certain plans, utilizing AI for efficiency, and adjusting prices to recover and grow [10].